mRNA Therapeutics CDMO Global Market Opportunities And Strategies To 2035

mRNA Therapeutics CDMO Market Definition

The messenger ribonucleic acid (mRNA) therapeutics contract development and manufacturing organization (CDMO) is a specialized service provider that supports pharmaceutical and biotechnology companies in the development, scale-up, and commercial manufacturing of mRNA-based medicines. These organizations offer integrated services such as mRNA synthesis, lipid nanoparticle (LNP) formulation, analytical testing, process optimization, and GMP-compliant production for clinical and commercial use. The primary purpose of an mRNA therapeutics CDMO is to enable fast, reliable, and high-quality production of mRNA-based drugs and vaccines without requiring companies to build in-house manufacturing facilities. The mRNA Therapeutics CDMO market consists of sales by entities (organizations, sole traders and partnerships) of mRNA Therapeutics CDMO provide contract development and manufacturing services for mRNA-based products used across multiple therapeutic and research applications. These services are used to support the development and production of preventive vaccines for infectious diseases, therapeutic vaccines for oncology, protein replacement therapies, gene editing and cell therapy support through mRNA delivery, and rare and genetic disease treatments.

mRNA Therapeutics CDMO Market Segmentation

The mRNA therapeutics CDMO market is segmented by type of service, by indication, by application and by end-user.

By Type Of Service –
The mRNA therapeutics CDMO market is segmented by type of service into:

• a) Development Services
• b) Manufacturing Services
• c) Laboratory Services

The manufacturing services market was the largest segment of the mRNA therapeutics CDMO market segmented by type of service, accounting for 47.5% or $2,253.9 million of the total in 2025. Going forward, the manufacturing services segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by type of service, at a CAGR of 13.5% during 2025-2030.

By Indication –
The mRNA therapeutics CDMO market is segmented by indication into:

• a) Infectious Diseases
• b) Metabolic And Genetic Diseases
• c) Cardiovascular And Cerebrovascular Diseases
• d) Oncology
• e) Other Indications

The infectious diseases was the largest segment of the mRNA therapeutics CDMO market segmented by indication, accounting for 38.0% or $1,800.7 million of the total in 2025. Going forward, the oncology segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by indication, at a CAGR of 12.4% during 2025-2030.

By Application –
The mRNA therapeutics CDMO market is segmented by application into:

1. a) Viral Vaccines
2. b) Protein Replacement Therapies
3. c) Cancer Immunotherapies

The viral vaccines market was the largest segment of the mRNA therapeutics CDMO market segmented by application, accounting for 40.1% or $1,901.8 million of the total in 2025. Going forward, the cancer immunotherapies segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by application, at a CAGR of 12.9% during 2025-2030.

By End User –
The mRNA therapeutics CDMO market is segmented by end user into:

• a) Pharmaceutical Companies
• b) Biotechnology Companies
• c) Academic Institutions
• d) Research Organizations

The biotechnology companies market was the largest segment of the mRNA therapeutics CDMO market segmented by end user, accounting for 64.7% or $3,066.6 million of the total in 2025. Going forward, the biotechnology companies segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by end user, at a CAGR of 12.9% during 2025-2030.

By Geography - The mRNA therapeutics CDMO market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Taiwan
o South East Asia
• Indonesia
o North America
• USA
• Canada
o South America
• Brazil
o Western Europe
• France
• Germany
• UK
• Italy
• Spain
o Eastern Europe
• Russia
o Middle East
o Africa

North America was the largest region in the mRNA therapeutics CDMO market, accounting for 38.0% or $1,802.6 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the mRNA therapeutics CDMO market will be Asia Pacific and South America where growth will be at CAGRs of 14.3% and 11.6% respectively. These will be followed by Eastern Europe and Africa where the markets are expected to grow at CAGRs of 11.4% and 9.1% respectively.

mRNA Therapeutics CDMO Market Competitive Landscape

Major Competitors are:

Lonza Group

Thermo Fisher Scientific Inc. (Patheon)

Samsung Biologics Co. Ltd.

Wuxi Biologics (WuXi Vaccines)

Catalent, Inc. (Catalent Biologics Inc.)

Other Competitors Include:

Danaher Corp. (Aldevron)

Merck KGaA (Merck Millipore)

AGC Biologics GmbH

Genscript Biotech Corp. (ProBio)

FUJIFILM Holdings Corporation (Fujifilm Pharmaceuticals U.S.A., Inc)

Corden Pharma Corp.

Recipharm AB

GC Biopharma

ST Pharm

Southern RNA

Rentschler Biopharma

IDT Biologika

Richter-Helm BioLogics GmbH & Co. KG

Polpharma Biologics Group B.V.

Novocol Pharma

Therapure Biopharma

BIOVECTRA

Ethris AG

Bionova Scientific Inc.

Hongene Biotech Corporation

Moderna

TriLink BioTechnologies LLC

Bio-Synthesis Inc.

Novartis' Brazilian

Insud Pharma Group

Eurofarma Laboratórios

Sinergium Biotech

Lifera

Biocina Pty Ltd

Biomay AG

mRNA Therapeutics CDMO Market Drivers

The key drivers of the mRNA therapeutics Cdmo market include: Growth In Multi-Valent And Combination mRNA Vaccines The growth in multi-valent and combination mRNA vaccines is expected to propel the growth of the mRNA therapeutics CDMO market in the forecast period. Drug developers are increasingly designing vaccines that target multiple pathogens or variants in a single product to enhance protection and streamline immunization programs. These advanced formulations involve greater manufacturing complexity, higher regulatory standards, and sophisticated delivery technologies, which many companies prefer to outsource. CDMOs offering end-to-end mRNA services, including sequence design, lipid nanoparticle formulation, large-scale production, and fill-finish operations, are well positioned to benefit. As clinical pipelines broaden and commercialization accelerates, demand for specialized CDMO partners is projected to rise significantly across global markets. Therefore, the growth in multi-valent and combination mRNA vaccines will drive the growth of the mRNA therapeutics CDMO market. The growth in growth in multi-valent and combination mRNA vaccines growth contribution during the forecast period in 2025 is 1.5%.

mRNA Therapeutics CDMO Market Restraints

The key restraints on the mRNA therapeutics CDMO market include: Instability And Degradation Of RNA Targets Instability and degradation of RNA targets is expected to hinder the growth of the mRNA therapeutics CDMO market in forecast period. mRNA is highly sensitive to temperature, enzymes, and environmental conditions, requiring strict cold-chain logistics, specialized storage, and advanced formulation technologies to maintain product integrity. These challenges increase manufacturing complexity, operational costs, and the risk of product loss during production and distribution. For some developers, these technical barriers can delay development timelines or limit large-scale commercialization. CDMOs must invest heavily in stabilization technologies, quality controls, and infrastructure, which may constrain capacity expansion and profitability. Therefore, stability and degradation of RNA targets may hinder the growth of the mRNA therapeutics CDMO market. Growth affected by instability and degradation of RNA targets during the forecast period in 2025 is -2.0%.

mRNA Therapeutics CDMO Market Trends

Major trends shaping the mRNA therapeutics CDMO market include: Integrated Sequence Optimization And GMP Manufacturing Partnership Accelerates mRNA Program Development Companies operating in the mRNA therapeutics CDMO market are focusing on strategic partnerships to integrate advanced mRNA sequence optimization with end-to-end GMP manufacturing, aiming to streamline development, reduce timelines, and accelerate clinical and commercial readiness. For instance, in November 2025, BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), partnered with Revolution Biomanufacturing Inc., a US-based, veteran- and woman-led contract development and manufacturing organization (CDMO) to deliver fully integrated mRNA design and GMP manufacturing services, creating a streamlined pathway from sequence engineering to sterile drug product supply. The collaboration combines Revolution Biomanufacturing’s proprietary UTR and AI-driven codon optimization platforms, designed to enhance mRNA stability and protein expression with BIOVECTRA’s end-to-end capabilities in process development, scale-up, and regulated production of pDNA, mRNA, lipid nanoparticles, and fill-finish services. By uniting advanced sequence optimization with commercial-grade manufacturing under a single workflow, the alliance aims to reduce development risks, shorten timelines, and support faster clinical progress for mRNA therapeutics, vaccines, and gene-editing programs. Advancement Of Next-Generation Lipid Nanoparticle Delivery Platforms Key players operating in the mRNA therapeutics CDMO market are focusing on collaborative development of advanced lipid nanoparticle delivery platforms to enhance stability, targeted delivery, and scalable GMP manufacturing for next-generation RNA and mRNA therapeutics and vaccines. For instance, in September 2025, Evonik Industries AG, a Germany-based contract development and manufacturing organization (CDMO) company for the pharmaceutical industry, partnered with Ethris AG, a Germany-based clinical-stage biotechnology company to co-develop and commercialize an advanced lipid nanoparticle (LNP) platform for nucleic acid delivery, strengthening Evonik’s CDMO service portfolio. The collaboration integrates Ethris’ proprietary SNaP LNP technology designed to enhance thermostability, local retention, and targeted delivery with Evonik’s expertise in lipid processing, formulation development, and good manufacturing practice (GMP) manufacturing. Unlike conventional LNP systems that require ultra-cold storage and show organ accumulation, the new platform supports more stable formulations and innovative approaches such as aerosolized lung delivery for respiratory diseases. Together, the partners aim to accelerate RNA-based therapeutics and vaccines from early development through clinical production.

Opportunities And Recommendations In The mRNA Therapeutics CDMO Market

Opportunities – The top opportunities in the mRNA therapeutics CDMO market segmented by type of service will arise in the manufacturing services segment, which will gain $2,000.4 million of global annual sales by 2030. The top opportunities in the mRNA therapeutics CDMO market segmented by indication will arise in the infectious diseases segment, which will gain $1,301.0 million of global annual sales by 2030. The top opportunities in the mRNA therapeutics CDMO market segmented by application will arise in the cancer immunotherapies segment, which will gain $1,411.7 million of global annual sales by 2030. The top opportunities in the mRNA therapeutics CDMO market segmented by end user will arise in the biotechnology companies segment, which will gain $2,564.9 million of global annual sales by 2030. The mRNA therapeutics CDMO market size will gain the most in the USA at $1,031.0 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the mRNA therapeutics CDMO to focus on integrated partnerships for end-to-end mrna development, focus on collaborative lnp platform development for scalable mrna delivery, focus on rapid personalized mrna manufacturing integration, focus on expanding regional manufacturing capacity and integrated mrna capabilities, focus on high-growth manufacturing services and core technology bottlenecks, expand in emerging markets, continue to focus on developed markets, focus on expanding global cdmo distribution networks through strategic partnerships, focus on value-based tiered pricing with cost transparency, focus on scientific credibility and clinical evidence communication, focus on targeted engagement and strategic partnerships, focus on building specialized talent and partnership capabilities for biotechnology clients.